Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Merger or Acquisition (February 2014)
11 slides from Mayne Pharma's merger presentation, Feb 12, 2014
Slide 1: Acquisition of LORCET and ESGIC brand franchises
For personal use only Mayne Pharma Group Limited Acquisition of LORCET™ and ESGIC™ brand franchises 12 February 2014
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer For personal use only The following notice and disclaimer applies to this presentation (Presentation) and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. In
Slide 3: Important Notice and Disclaimer (cont'd)
Important Notice and Disclaimer (cont’d) For personal use only None of Mayne Pharma’s corporate or financial advisers nor any advisers, financiers or underwriters appointed (being Credit Suisse (Australia) Limited and UBS AG, Australia Branch) (or to be appointed) in respect of any potential offerin
Slide 4: Transaction overview
Transaction overview For personal use only Mayne Pharma Group Limited (“Mayne Pharma”) has acquired selected brands from Forest Laboratories, Inc. (“Forest”) for up to US$12.0m comprising − An upfront cash payment of US$10.0m; plus − An earn-out of up to US$2.0m, payable quarterly based on sales p
Slide 5: Overview of acquired products
Overview of acquired products Narcotic analgesic used for the relief of moderate to moderately severe pain For personal use only LORCET™ Combination product containing hydrocodone and acetaminophen (paracetamol or “APAP”) in tablet form Product first launched in 1984 and had 2013 sales of US$3m,
Slide 6: Market overview
Market overview For personal use only LORCET™ and ESGIC™ compete in attractive growth markets ● Hydrocodone/APAP is the largest oral LORCET market1 solid dosage product by volume in the US By value (US$m) CAGR with over 7bn tablets sold and US$1bn in 500 22% sales p.a. according to IMS Health; 400 -
Slide 7: Acquisition funding
Acquisition funding For personal use only Acquisition has been completed and settled via a mix of available short term debt and cash reserves This will be replaced with the proceeds of an A$18.0m underwritten placement to institutional and sophisticated investors The placement will be conducte
Slide 8: Placement timetable
Placement timetable1 For personal use only Trading halt in Mayne Pharma shares Wednesday 12th February 2014 Bookbuild opens 10:00am, Wednesday 12th February 2014 Bookbuild closes 5:00pm, Wednesday 12th February 2014 Mayne Pharma shares recommence trading Thursday 13th February 2014 Settlement of the
Slide 9: Mayne Pharma's product portfolio
Mayne Pharma’s product portfolio * Highlights products added recently US Rest of world For personal use only • Amiodarone • Aspirin • Bromfenac sodium • Doxycycline hyclate • Butalbital/APAP/Caffeine • Erythromycin • Doxycycline hyclate (now launched On market – 150mg*) • Erythromycin generic • Liot
Slide 10: Foreign Selling Restrictions
Foreign Selling Restrictions International Offer Restrictions For personal use only This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. New Shares may not be offered or sold in any country outside Australi
Slide 11: Foreign Selling Restrictions (cont'd)
Foreign Selling Restrictions (cont’d) For personal use only Singapore This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other
Mayne Pharma Group — Merger or Acquisition (February 2014) on 6ix